Related Experiment Video
Updated: Jun 2, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
The role of tumour-derived mIL-4 on rat C6 glioma regression
Abstract:
Interleukin-4 (IL-4) has been demonstrated to possess anti-tumourigenic properties in vivo which is attributed to the infiltration of eosinophils in addition to an inhibition of tumour vascularisation. We have previously generated stable transfectants of C6 glioma cells that express mouse IL-4 (mIL-4) under a tetracycline-responsive promoter system, enabling us to apply tight regulatory control of mIL-4 expression in vivo. We have demonstrated that the subcutaneous implantation of mIL-4 expressing rat C6 glioma cell lines in nu/nu mice resulted in an inhibition of tumour growth. In this study, we have investigated the ability of mIL-4 to potentiate the regression of established subcutaneous rat C6 tumours in nu/nu mice. Induction of mIL-4 re-expression in established tumours did not cause a regression of tumour growth as determined by external tumour volume measurements. However, histological analysis revealed that mIL-4 re-expressing tumours were highly necrotic, were infiltrated by eosinophils and had a reduced level of vascularisation. These results suggest that mIL-4 can potentiate an anti-tumourigenic response in established C6 tumours in nu/nu mice. Furthermore, this study illustrates the need for detailed and defined tumour histopathology as tumour volume measurements alone can lead to inaccurate and misleading results.
Insights
Mouse Interleukin-4 (mIL-4) can promote anti-tumourigenic responses in established C6 glioma tumors. Histological analysis revealed increased necrosis and eosinophil infiltration, highlighting the importance of detailed tumor pathology beyond volume measurements.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Interleukin-4 (IL-4) exhibits anti-tumourigenic effects in vivo, linked to eosinophil infiltration and reduced tumor vascularization.
- Stable C6 glioma cell transfectants expressing mouse IL-4 (mIL-4) under a tetracycline-responsive promoter allow controlled in vivo expression.
- Previous studies showed subcutaneous implantation of mIL-4 expressing C6 glioma cells inhibited tumor growth in nu/nu mice.
Purpose of the Study:
- To investigate the potential of mIL-4 to promote regression of established subcutaneous rat C6 tumors in nu/nu mice.
- To assess the impact of induced mIL-4 re-expression on established tumor growth and characteristics.
Main Methods:
- Established subcutaneous rat C6 tumors in nu/nu mice were induced to re-express mIL-4.
- Tumor growth was monitored via external volume measurements.
- Histological analysis was performed to evaluate tumor necrosis, eosinophil infiltration, and vascularization.
Main Results:
- Re-induction of mIL-4 did not significantly alter external tumor volume measurements.
- Histological examination revealed substantial necrosis in mIL-4 re-expressing tumors.
- Significant infiltration of eosinophils and reduced vascularization were observed in tumors with mIL-4 re-expression.
Conclusions:
- mIL-4 can potentiate an anti-tumourigenic response in established C6 tumors, characterized by necrosis and immune cell infiltration.
- Tumor volume measurements alone may be insufficient for accurately assessing therapeutic effects; detailed histopathology is crucial.
- These findings support the role of IL-4 in modulating the tumor microenvironment for anti-cancer effects.
